" /> Asciminib - CISMeF





Preferred Label : Asciminib;

NCIt definition : An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph ) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.;

UNII : L1F3R18W77;

InChIKey : VOVZXURTCKPRDQ-CQSZACIVSA-N;

CAS number : 1492952-76-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1492952-76-7 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : ABL-001; ABL 001;

NCI Metathesaurus CUI : CL472320;

Codes from synonyms : 53780;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.